secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001628280-26-001768
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio: 88% HDV RNA undetectable at Week 96 in combo arm; cash ~$781M, runway to Q4 2027
--------------------------------------------------------------------------------

- Phase 2 SOLSTICE: 88% (21/24) of combo arm achieved undetectable HDV RNA at Week 96 vs 46% (11/24) monotherapy.
- No grade 3+ treatment-related AEs in combo arm; generally mild/moderate and transient.
- Cash, cash equivalents & investments ~$781M at Dec 31, 2025; runway extended into Q4 2027 via Norgine deal.
- ECLIPSE 1 Phase 3 topline data expected Q4 2026; ECLIPSE 2/3 top-line in Q1 2027.
- VIR-5500 Phase 1 data in prostate cancer to be presented at ASCO GU Feb 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/0001628280-26-001768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828026001768/vir-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-001768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer